文献速递妇科肿瘤

Trebananib或安慰剂联合卡铂和紫杉醇作为晚期卵巢癌一线治疗(TRINOVA-3/ENGOT-ov2/GOG-3001):一项随机、双盲、3期试验

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-05-07

TRINOVA-3是一项多中心、 multinational、双盲3期试验,纳入1015例FIGO III-IV期上皮性卵巢癌、原发性腹膜癌或输卵管癌患者,随机2:1接受trebananib或安慰剂联合卡铂和紫杉醇一线治疗。中位随访27.4个月,trebananib组中位无进展生存期15.9个月 vs 安慰剂组15.0个月(HR 0.93,95%CI 0.79-1.09;p=0.36),差异无统计学意义。Trebananib联合方案未改善无进展生存期,未产生新的安全性信号。

要点

  • Trebananib联合卡铂和紫杉醇一线治疗晚期卵巢癌未改善无进展生存期(HR 0.93,95%CI 0.79-1.09;p=0.36)。
  • Trebananib组3级及以上治疗中出现的不良事件发生率为76%(512/675),安慰剂组为71%(237/336)。
  • Trebananib组严重不良事件发生率为40%(269/678),安慰剂组为31%(104/337)。

核心结论

  • Trebananib联合卡铂和紫杉醇作为晚期卵巢癌一线治疗未改善无进展生存期,未产生新的安全性信号,在该患者人群中效果有限。

研究设计与样本

  • TRINOVA-3是一项多中心、跨国、3期、双盲研究,在14个国家的206个研究中心进行。
  • 纳入1015例18岁及以上、活检确诊的FIGO III-IV期上皮性卵巢癌、原发性腹膜癌或输卵管癌、ECOG体能状态0或1的患者,随机2:1分配至trebananib组(678例)或安慰剂组(337例)。
  • 治疗方案为每3周一次紫杉醇175 mg/m2和卡铂(AUC 5或6)共6周期,联合每周静脉trebananib 15 mg/kg或安慰剂,维持治疗最多额外18个月。
  • 主要终点为研究者评估的意向治疗人群无进展生存期;安全性分析纳入至少接受一剂研究治疗的患者。

主要发现

  • 中位随访27.4个月(IQR 17.7-34.2),trebananib组678例中405例(60%)发生无进展生存事件,安慰剂组337例中221例(66%)发生。
  • Trebananib组中位无进展生存期15.9个月(95%CI 15.0-17.6)vs 安慰剂组15.0个月(95%CI 12.6-16.1),HR 0.93(95%CI 0.79-1.09;p=0.36)。
  • Trebananib组675例中512例(76%)和安慰剂组336例中237例(71%)发生3级及以上治疗中出现的不良事件;最常见为中性粒细胞减少(trebananib组238例[35%] vs 安慰剂组126例[38%])、贫血(76例[11%] vs 40例[12%])和白细胞减少(81例[12%] vs 35例[10%])。
  • Trebananib组269例(40%)和安慰剂组104例(31%)发生严重不良事件。
  • Trebananib组有2例致命不良事件被认为与trebananib、紫杉醇和卡铂相关(肺部感染和中性粒细胞减少性结肠炎);2例被认为与紫杉醇和卡铂相关(一般身体健康状况恶化和血小板计数下降);安慰剂组无治疗相关致命不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial. METHODS: TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres) in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III to IV epithelial ovarian, primary peritoneal, or fallopian tube cancers, and an ECOG performance status of 0 or 1. Eligible patients were randomly assigned (2:1) using a permuted block method (block size of six patients) to receive six cycles of paclitaxel (175 mg/m2) and carboplatin (area under the serum concentration-time curve 5 or 6) every 3 weeks, plus weekly intravenous trebananib 15 mg/kg or placebo. Maintenance therapy with trebananib or placebo continued for up to 18 additional months. The primary endpoint was progression-free survival, as assessed by the investigators, in the intention-to-treat population. Safety analyses included patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01493505, and is complete. FINDINGS: Between Jan 30, 2012, and Feb 25, 2014, 1164 patients were screened and 1015 eligible patients were randomly allocated to treatment (678 to trebananib and 337 to placebo). After a median follow-up of 27·4 months (IQR 17·7-34·2), 626 patients had progression-free survival events (405 [60%] of 678 in the trebananib group and 221 [66%] of 337 in the placebo group). Median progression-free survival did not differ between the trebananib group (15·9 months [15·0-17·6]) and the placebo group (15·0 months [12·6-16·1]) groups (hazard ratio 0·93 [95% CI 0·79-1·09]; p=0·36). 512 (76%) of 675 patients in the trebananib group and 237 (71%) of 336 in the placebo group had grade 3 or worse treatment-emergent adverse events; of which the most common events were neutropenia (trebananib 238 [35%] vs placebo 126 [38%]) anaemia (76 [11%] vs 40 [12%]), and leucopenia (81 [12%] vs 35 [10%]). 269 (40%) patients in the trebananib group and 104 (31%) in the placebo group had serious adverse events. Two fatal adverse events in the trebananib group were considered related to trebananib, paclitaxel, and carboplatin (lung infection and neutropenic colitis); two were considered to be related to paclitaxel and carboplatin (general physical health deterioration and platelet count decreased). No treatment-related fatal adverse events occurred in the placebo group. INTERPRETATION: Trebananib plus carboplatin and paclitaxel did not improve progression-free survival as first-line treatment for advanced ovarian cancer. The combination of trebananib plus carboplatin and paclitaxel did not produce new safety signals. These results show that trebananib in combination with carboplatin and paclitaxel is minimally effective in this patient population. FUNDING: Amgen.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Vergote I, Scambia G, O'Malley DM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019. PMID: 31076365. doi:10.1016/S1470-2045(19)30178-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。